Inici › Càncer de bufeta › Ohio › Columbus
Assaigs clínics de Càncer de bufeta a Columbus, OH
19 estudis de Càncer de bufeta busquen participants en centres de Columbus i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
ReclutantFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- i 8 més
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
ReclutantFase 2
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- Doctors Hospital, Columbus
- i 1 més
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
ReclutantFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
ReclutantFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
ReclutantFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- i 11 més
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
ReclutantFase 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
ReclutantFase 1
- Ohio State University, Columbus
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
ReclutantFase 2
- Ohio State University, Columbus
- Central Ohio Urology Group (US Urology Partners), Gahanna · a 7 mi
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
ReclutantFase 1
- The Ohio State University (OSU), Columbus
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
ReclutantFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
ReclutantFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
ReclutantFase 1/2
- Central Ohio Urology Group, Gahanna · a 7 mi
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
ReclutantEstudi observacional
- The Ohio State University, Columbus
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
ReclutantFase 2/3
- The James Outpatient Care West Campus, Columbus
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
ReclutantFase 2
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
ReclutantFase 2
- Ohio State University Hospital, Columbus
- Ohio State University, Columbus
- OSU Wexner Medical Center & James Cancer Hospital, Columbus
- i 2 més
Blue Light Cystoscopy With Cysview® Registry
ReclutantEstudi observacional
- Ohio State University Wexner Medical Center, Columbus
- Ohio State University, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Columbus
Assaigs de Càncer de bufeta en altres ciutats
- New York City, NY35 estudis
- Nashville, TN31 estudis
- Houston, TX31 estudis
- Dallas, TX27 estudis
- Boston, MA26 estudis
- Washington, DC26 estudis
- Los Angeles, CA24 estudis
- Baltimore, MD24 estudis
- St. Louis, MO22 estudis
- Philadelphia, PA21 estudis
- Seattle, WA21 estudis
- Edison, NJ21 estudis
Altres estudis a Columbus
- Càncer de pulmó de cèl·lules no petites56 estudis
- Càncer de mama39 estudis
- Càncer d'ovari39 estudis
- Càncer (tots els tipus)38 estudis
- Càncer de pulmó37 estudis
- Leucèmia mieloide aguda35 estudis
- Leucèmia limfàtica crònica28 estudis
- Càncer metastàtic27 estudis
- Càncer d'endometri25 estudis
- Càncer colorrectal24 estudis
- Càncer de pròstata24 estudis
- Mieloma múltiple24 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.